Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer

Asia-Pacific Journal of Clinical Oncology

Volumn 10, Issue 4, 2014, Pages 322-329

  Suenaga, Mitsukuni ^a   Mizunuma, Nobuyuki ^a   Matsusaka, Satoshi ^a   Shinozaki, Eiji ^a   Ueno, Masashi ^a   Yamaguchi, Toshiharu ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Bevacizumab; FOLFOX4; Metastatic colorectal cancer; Overall survival; Progression free survival

Indexed keywords

ANTICOAGULANT AGENT; BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PANITUMUMAB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGED; ALLERGIC REACTION; ANOREXIA; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; COLITIS; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FISTULA; FISTULATION; FOLLOW UP; GASTROINTESTINAL PENETRATION; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; HYPERTENSION; INTERSTITIAL PNEUMONIA; INTESTINE OBSTRUCTION; JAPANESE (PEOPLE); LIVER FAILURE; LIVER METASTASIS; LUNG EMBOLISM; LUNG METASTASIS; LYMPH NODE METASTASIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MUCOSAL BLEEDING; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PELVIS ABSCESS; PERIPHERAL NEUROPATHY; PERITONEUM METASTASIS; PROGRESSION FREE SURVIVAL; PROTEINURIA; RETROSPECTIVE STUDY; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN METASTASIS; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; TREND STUDY; VENOUS THROMBOEMBOLISM; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; ELECTRONIC MEDICAL RECORD; JAPAN; MIDDLE AGED; NEOPLASM METASTASIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; ELECTRONIC HEALTH RECORDS; FEMALE; FLUOROURACIL; HUMANS; JAPAN; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84909993854     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12094     Document Type: Article

References (15)

1. National Cancer Center, Center for Cancer Control and Information Services. Cancer Statistics in Japan. 2012. [Cited 15 Jan 2013]. Available from: http://ganjoho.jp/public/statistics/backnumber/2012_en.html.
2. Hurwitz H, Fehrenbacher L, Novotny W etal. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
3. Kabbinavar F, Hurwitz HI, Fehrenbacher L etal. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.
4. Kabbinavar FF, Schulz J, McCleod M etal. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697-3705.
5. Saltz LB, Clarke S, Díaz-Rubio E etal. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
6. Giantonio BJ, Catalano PJ, Meropol NJ etal. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544.
7. Goldberg RM, Sargent DJ, Morton RF etal. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
8. Tournigand C, André T, Achille E etal. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
9. Grothey A, Sugrue MM, Purdie DM etal. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26: 5326-5334.
10. Van Cutsem E, Rivera F, Berry S etal. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20: 1842-1847.
11. Loupakis F, Bria E, Vaccaro V etal. Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. J Exp Clin Cancer Res 2010; 29: 58.
12. Welch S, Spithoff K, Rumble RB, Maroun J; Gastrointestinal Cancer Disease Site Group. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol 2010; 21: 1152-1162.
13. Tournigand C, Cervantes A, Figer A etal. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006; 24: 394-400.
14. Chibaudel B, Maindrault-Goebel F etal. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009; 27: 5727-5733.
15. Bennouna J, Sastre J, Arnold D etal. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14: 29-37.